Antiplatelet agents and stroke prevention

Seminars in Neurology

Volumn 18, Issue 4, 1998, Pages 441-450

  Dyken, Mark L ^a  

^a Building BA402   (United States)

Author keywords

Antiplatelet agents; Aspirin; Cerebral ischemia

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; TICLOPIDINE; WARFARIN;

BRAIN ISCHEMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0032419782     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040897     Document Type: Review

References (75)

1. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-316
2. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II. Surgical group. Stroke 1978;9:309-318
3. Ruether R, Dorndorf W. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions: the results of a double-blind trial. In: Breddin K, Dorndorf W, Lowe D, et al., eds. Acetylsalicylic Acid in Cerebral Ischemia and Coronary Heart Disease. Stuttgart: Schattauer, 1978:97-106
4. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299:53-59
5. Bousser MG, Eschwege E, Haguenau M, et al. Essai cooperatif controle AICLA: prevention secondaire des accidents ischemiquers cerebraux lies a l'atherosclerose par l'aspirine et le dipyridamole. Rev Neurol (Paris) 1981;5:33-41
6. Bousser MG, Eschwege E, Haguenau M, et al. "A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14:5-14
7. Sorenson PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish Cooperative Study. Stroke 1983;13:15-22
8. A Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987;18:325-334
9. Boysen G, Sorensen PS, Juhler M, et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988;19:1211-1215
10. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988;296: 317-320
11. UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054
12. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349
13. European Stroke Prevention study Group. ESPS: principal end points. Lancet 1987;2:1351-1355
14. ESPS Group. European Stroke Prevention Study. Stroke 1990; 21:1122-1130
15. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
16. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106
17. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-331
18. Dyken ML. Antiplatelet aggregating agents in transient ischemic attacks and the relationship of risk factors: total experience of six medical centers. In: Breddin K, Lowe D, Uberla K, et al., eds. Prophylaxis of Venous, Peripheral, Cardiac and Cerebral Vascular Diseases with Acetylsalicylic Acid. V. Colfarit-Symposium. Mainz, Germany: Stuttauer-Verlag, 1981:141-148
19. Masuhr F, Busch M, Einhaupl KM. Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe. Stroke 1998:339-345
20. Weksler BB, Kent JL, Rudolph D, Scherer PB, Levy DE. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 1985;16:5-9
21. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg/day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266
22. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-199
23. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-542
24. O'Connor CM, Fisher M, O'Gara P, et al. for the CARS Investigators. The importance of aspirin dose in the protection of non-hemorrhagic stroke following acute myocardial infarction: insights from the Coumadin Aspirin Reinfarction Study (CARS) [abstract]. Circulation 1996;94(Suppl):I80-I81
25. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-396
26. Dyken ML, Barnett HJM, Easton JD, et al. Low-dose aspirin and stroke: "It ain't necessarily so" [editorial]. Stroke 1992;23: 1395-1399
27. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the on-going Physicians' Health Study. N Engl J Med 1988;318:262-264
28. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135
29. Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993;87: 1873-1879
30. Ranke C, Creutzig A, Luska G, et al. Controlled trial of high-virus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Invest 1994;72:673-680
31. Feng D, McKenna C, Murillo J, et al. Effect of aspirin dosage and enteric coating on platelet reactivity. Am J Cardiol 1997;80:189-193
32. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. The effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23:1400-1403
33. Masotti GG, Galanti L, Pogessi R, Abbate R. Differential inhibition of prostacylcin production and platelet aggregation by aspirin. Lancet 1979:2;1213-1216
34. Lejeune L, Fattet M, Degos JD. Aspirin dose, bleeding time, platelet adhesion and aggregation in cerebral thrombosis. Int J Clin Pharmacol Ther Toxicol 1988;26:237-242
35. O'Brien JR, Etherington MD. How much aspirin? Thromb Haemost 1990;64:486
36. Buerke M, Pittroff W, Meyer J, Darius H. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995;130:465-472
37. Caterina RD, Giannessi D, Boem A, et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 1985;54:528-532
38. Akopov SS, Grigorian GS, Gabrielian ES. Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis. J Clin Pharmacol 1992;32:133-135
39. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992;85:1077-1082
40. Roald HE, Orvim U, Bakken IJ, Barstad RM, Kierulf P, Sakariassen KS. Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Arterioscler Thromb 1994;14:617-621
41. Uchiyama S, Yamazaki M, Maruyama S, et al. Shear-induced platelet aggregation and its inhibition by antiplatelet agents in cerebral ischemia. Clin Hemorheol 1993;13:623-636
42. Uchiyama S, Yamazaki M, Maruyama S, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994;25:1547-1551
43. Hormes JT, Austin JH, James G, et al. Toward an optimal "antiplatelet" dose of aspirin: preliminary observations. J Stroke Cerebrovasc Dis 1991;1:27-35
44. Winocour PD, Watala C, Perry DW, Kiniough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 1992;68:577-582
45. Szczeklik A, Krzanaowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. J Blood 1992;80:2006-2011
46. Bernhardt J, Konstantin R, Lüscher TF, Bühler FR, Resink T. Acetysalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993;21: 973-976
47. VanPampus ECM, Huijgens PC, Zevenbergen A, Twaalfhoven H, VanKamp GJ, Langenhuijsen MMAC. Influence of aspirin on human megakaryocyte prostaglandin synthesis. Eur J Haematol 1993;50:264-268
48. Walters TK, Mitchell DC, Wood RF. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg 1993;80:1266-1268
49. Lacoste L, Lam JYT, Letchacovski G. Comparative antithrombotic efficacy of aspirin: 80 mg vs 325 mg daily [abstract 2971]. Circulation 1994;90(suppl):I-552
50. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997;95:63-68
51. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-355
52. Ackerman RH, Newman KL. Incomplete antiplatelet effects in patients on aspirin compounds. Ann Neurol 1990;28:224
53. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350
54. Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of aspirin treatment after stroke. Stroke 1994;25:275-277
55. Munson RJ, Sharpe BL, Finan JW, Eliasziw M, Hachinski VC, Barnett HJM. The NASCET experience of bleeding complications of patients on aspirin [abstract]. Stroke 1997;28:232
56. Munson R, Sharpe B, Finan J, Eliasziw M, Hachinski VC, Barnett HJM. Aspirin dose and bleeding complications in the North American Symptomatic Carotid Endarterectomy Trial [abstract]. J Stroke Cerebrovasc Dis 1997;6:468
57. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-aggregants plaquettaires. Rev Neurol (Paris) 1982;138:367-385
58. American-Canadian Co-Operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II. Endpoint results. Stroke 1985;16:406-415
59. Kaye J. A Trial to Evaluate the Relative Roles of Dipyridamole and Aspirin in the Prevention of Deep Vein Thrombosis in Stroke Patients. Bracknell, Berkshire: Boehringer Ingelheim, (Boehringer Ingelheim internal report), 1990
60. Enserink M. Clinical trials. Fraud and ethics charges hit stroke drug trial. Science 1996;274:2004-2005
61. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507
62. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220
63. CAPRIE Steering Committeee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
64. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511
65. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1: 175-179
66. Stroke prevention in atrial fibrillation investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 1990;322:863-868
67. Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-539
68. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262
69. Ezekowitz MD, Bridgers SL, James KE, et al. for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412
70. Sherman DG, Dyken ML, Gent M, Harrison MJG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995;108(suppl):444S-456S
71. International Stroke Trial Collaborative Group. The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581
72. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: Randomised, placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349: 1641-1649
73. Bousser MG. Aspirin or heparin immediately after a stroke [commentary]? Lancet 1997;349:1564-1565
74. Kronmal RA, Hart RG, Manolio TA, et al. for the CHS Collaborative Research Group. Aspirin use and incident stroke in the Cardiovascular Health Study. Stroke 1998;29:887-894
75. Buring JE, Bogousslavsky J, Dyken M. Aspirin and stroke [editorial]. Stroke 1998;29:885-886